Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin
This study has been completed.
Sponsored by: Kowa Research Europe
Information provided by: Kowa Research Europe
ClinicalTrials.gov Identifier: NCT00309738
  Purpose

The purpose of this study is to compare the efficacy and safety of pitavastatin with that of simvastatin in patients with risk factors for heart disease.


Condition Intervention Phase
Hypercholesterolemia
Dyslipidemia
Drug: pitavastatin
Drug: simvastatin
Phase III

Genetics Home Reference related topics: hypercholesterolemia
MedlinePlus related topics: Cholesterol Heart Diseases
Drug Information available for: Simvastatin Pitavastatin NK 104
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Study of Pitavastatin Vs. Simvastatin (Following Up-Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia and 2 or More Risk Factors for Coronary Heart Disease

Further study details as provided by Kowa Research Europe:

Primary Outcome Measures:
  • Percent change from baseline in low density lipoprotein-cholesterol (LDL-C)

Secondary Outcome Measures:
  • Changes from baseline in other lipid and lipoprotein fractions
  • Safety and tolerability of pitavastatin

Estimated Enrollment: 300
Study Start Date: November 2005
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and females (18-75 years of age)
  • At least two cardiovascular disease risk factors
  • Must have been following a restrictive diet
  • Diagnosis of primary hypercholesterolemia or combined dyslipidemia

Exclusion Criteria:

  • Homozygous familial hypercholesterolemia
  • Conditions which may cause secondary dyslipidemia
  • Uncontrolled diabetes mellitus
  • Abnormal pancreatic, liver or renal function
  • Abnormal serum creatine kinase (CK) above the pre-specified level
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00309738

Locations
Denmark
CCBR a/S
Aalborg, Denmark
CCBR a/S
Vejle, Denmark
CCBR a/S
Ballerup, Denmark
Kolesterollaboratoriet
Hellerup, Denmark
Y Forskning, Bispebjerg Hospital
Copenhagen NV, Denmark
Frederiks Hospital, Kardiologisk
Frederiksberg, Denmark
Netherlands
Mathenesserlaan 247
Rotterdam, Netherlands
Damsterdiep 9
Groningen, Netherlands
Parkdreef 142
Zoetermeer, Netherlands
Reigerstraat 30
Velp, Netherlands
Doezastraat 1
Leiden, Netherlands
Kamerlingh Onnesstraat 16-18
Nijmegen, Netherlands
Middellaan 5
Breda, Netherlands
Bomanshof 8
Eindhoven, Netherlands
Spain
Hospital Universitario de Bellvitge
Barcelona, Spain
Hospital Clinico Universitario de Santiago
Santiago de Compostela, Spain
Hospital de Sagunto
Valencia, Spain
Hospital Universitario Reina Sofia
Cordoba, Spain
Fundacion Jimenez Diaz
Madrid, Spain
Hospital Clinico San Carlos
Madrid, Spain
Hospital Ramon y Cajal
Madrid, Spain
Hospital Vall d'Hebron
Barcelona, Spain
Spain, Alicante
Hospital Clinico S. Juan de Alicante
San Juan, Alicante, Spain
Spain, Barcelona
Hospital Clinic i Provincial
Villaroel, Barcelona, Spain
Sweden
Karolinska Universitetssjukhuset
Stockholm, Sweden
Medicinkliniken
Ludvika, Sweden
Sahlgrenska University Hospital, Intermedicin
Gothenburg, Sweden
Hjartmottagningen
Malmo, Sweden
Narsjukhuset Sandviken, Kardiologlab, Medicin
Sandviken, Sweden
Hjarthuset AB
Varberg, Sweden
Hjartmottagningen
Helsingborg, Sweden
Lakarcentrum Nyponet
Karineholm, Sweden
Hjart & Karlcenter
Sodertalje, Sweden
Huslakaren i Sandviken
Sandviken, Sweden
Angelholms Sjukhus, Medicinkliniken
Angelhom, Sweden
Sponsors and Collaborators
Kowa Research Europe
Investigators
Study Director: Dragos Budinski, Med Dr. Medical Director
  More Information

Study ID Numbers: NK-104-304
Study First Received: December 8, 2005
Last Updated: October 23, 2008
ClinicalTrials.gov Identifier: NCT00309738  
Health Authority: Sweden: Medical Products Agency;   Spain: Spanish Agency of Medicines

Keywords provided by Kowa Research Europe:
Kowa
KRE
Hypercholesterolemia
combined dyslipidemia
dyslipidemia
pitavastatin
NK-104
simvastatin

Study placed in the following topic categories:
Coronary Disease
Metabolic Diseases
Hyperlipidemias
Heart Diseases
NK 104
Simvastatin
Metabolic disorder
Hypercholesterolemia
Dyslipidemias
Coronary Artery Disease
Lipid Metabolism Disorders

Additional relevant MeSH terms:
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Antilipemic Agents
Enzyme Inhibitors
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009